ALS community petitions FDA to approve NurOwn stem cell therapy

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

A coalition of ALS patients and families has filed a 309‑page Citizens’ Petition with the FDA calling for accelerated approval of NurOwn, a stem cell therapy developed by BrainStorm Cell Therapeutics. The petition brings together over a decade of clinical and real-world evidence, including data from expanded access and right-to-try programs, according to the company.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE